PMVP News and Press, PMV Pharmaceuticals Inc.

PRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Off...

BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOn...

2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...

2024-05-09 13:54:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips PMV Pharma (NASDAQ: PMVP ) just reported results for the first quarter of 2024. PMV Pharma reported earnings per share of -30 cents. This was above the analyst estimate fo...

2024-05-09 10:57:17 ET More on PMV Pharmaceuticals Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Read the full article on Seeking Alpha For further details see: PMV Pharmaceuticals GAAP EPS of ...

First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking ora...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-04-11 21:15:01 ET Jefferies analyst issues BUY recommendation for PMVP on April 11, 2024 07:46PM ET. PMVP was trading at $1.58 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations ...

2024-04-11 21:00:03 ET Kambiz Yazdi from Jefferies issued a price target of $5.00 for PMVP on 2024-04-11 19:46:00. The adjusted price target was set to $5.00. At the time of the announcement, PMVP was trading at $1.58. The overall price target consensus is at $31.33 with...

Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT) First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients...